Key factors
sym | PSTV |
exch | US |
MCap | 8339.14K |
Beta | 0.595 |
EPS | -4.24 |
Div date | 0000-00-00 |
Yesterday
sym | PSTV |
exch | US |
close | 1.665 |
50 Day MA | 1.911 |
200 Day MA | 1.932 |
52 Week High | 5.1 |
52 Week Low | 0.97 |
Target Price | 28.2 |
Market Cap Mln | 8.339 |
Share statistics
Shares Outstanding | 4354.64K |
Shares Float | 4213.52K |
Percent Institutions | 3.272 |
PercentInsiders | 1.45 |
SharesShort | 32228 |
Short Ratio | 0.79 |
Shares Short Prior Month | 40790 |
Short Percent | 0.740 |
Income
Revenue TTM | 4913.0K |
Revenue Per Share TTM | 1.564 |
Quarterly Revenue Growth YOY | 769.50 |
Gross Profit TTM | -9474.0K |
EBITDA | -12.6M |
Diluted Eps TTM | -4.24 |
earning
Operating Margin TTM | -2.93 |
EPS Estimate Current Quarter | -1.07 |
EPS Estimate Current Year | -2.41 |
EPS Estimate Next Quarter | -0.53 |
EPS Estimate Next Year | -2.39 |
Earnings Share | -4.24 |
Dividend
Dividend Date | 2019-08-06 |
Last Split Date | 2023-05-01 |
Last Split Factor | 1:15 |
business
Enterprise Value Ebitda | -0.32 |
Enterprise Value Revenue | 18.19 |
Book Value /share | -0.30 |
Price Book MRQ | 3.760 |
Price Sales TTM | 1.697 |
ProfitMargin | -2.71 |
ReturnOnAssetsTTM | -0.47 |
ReturnOnEquityTTM | -5.22 |
Sector
Gic Group | Pharmaceuticals, Biotechnology & Life Sciences |
Gic Industry | Biotechnology |
Gic Sector | Health Care |
Gic Sub Industry | Biotechnology |
Industry | Biotechnology |
Sector | Healthcare |
Codes
ISIN | US72941H4002 |
CIK | 1095981 |
Code | PSTV |
CUSIP | 72941H103 |
CountryISO | US |
Currency Code | USD |
Currency Name | US Dollar |
Exchange | NASDAQ |
Currency Symbol | $ |
fund
Type | Common Stock |
UpdatedAt | 2024-04-05 |
Home Category | Domestic Primary |
info
Fiscal Year End | December |
Full Time Employees | 20.0 |
IPODate | 2000-11-16 |
MostRecent Quarter | 2023-12-31 |
Contact
Name | Plus Therapeutics Inc |
Address | 4200 Marathon Boulevard, Austin, TX, United States, 78756 |
Country Name | USA |
Phone | 737 255 7194 |
Web URL | https://plustherapeutics.com |
Logo URL | /img/logos/US/PSTV.png |
Plus Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. Its lead drug candidate is Rhenium-186Re obisbemeda, a patented radiotherapy that targets central nervous system cancers and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. The company also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere that is designed to treat various solid organ cancers comprising primary and secondary liver cancers by intra-arterial injection. It has license agreements with NanoTx, Corp. and The University of Texas Health Science Center at San Antonio. The company was formerly known as Cytori Therapeutics, Inc. and changed its name to Plus Therapeutics, Inc. in July 2019. Plus Therapeutics, Inc. was founded in 1996 and is headquartered in Austin, Texas.